Allena Pharmaceuticals Presents Phase 1 Data on ALLN-177 at American ...
Hyperoxaluria is a serious metabolic condition resulting from high oxalate levels in the urine due to either hyper-absorption of oxalate from the diet or from overproduction of oxalate by the liver. Based on this positive Phase 1 data, the company has ...
Business Wire (press release) - Mon, 17 Nov 2014 05:30

Allena Pharma's kidney stone-preventing enzyme attracts $25M
MedCity News - Mon, 17 Nov 2014 02:52

Allena Pharmaceuticals To Present Data on Lead Program ALLN-177 at ASN ...
Hyperoxaluria is a serious metabolic disorder and is one of the major risk factors for nephrolithiasis, nephrocalcinosis, and oxalate nephropathy that leads to chronic kidney disease. Hyperoxaluria is a direct result of either hyper-absorption of ...
Business Wire (press release) - Mon, 10 Nov 2014 05:30

4 More Biotech Stocks to Buy, With Up to 200% Upside
Tekmira has licensed its proprietary lipid nanoparticle delivery technology for exclusive use in Dicerna's primary hyperoxaluria type 1 development program. The company is also diligently working on an Ebola vaccine the targets the Guinea strain, which ...
24/7 Wall St. - Fri, 21 Nov 2014 05:51



Dicerna announces new license deal, plans first clinical results next year
The drug is intended to treat a rare, inherited liver disorder called primary hyperoxaluria type 1, and like all Dicerna's drugs, uses the same so-called RNA interference approach now being perfected by Cambridge-based Alnylam Pharmaceuticals. The ...
Boston Business Journal (blog) - Tue, 18 Nov 2014 03:37

Dicerna Announces License Agreement with Tekmira to Advance Dicerna's PH1 ...
Nanotechnology News (press release) - Mon, 17 Nov 2014 19:45

Dicerna Reports on Progress of Development Programs
Business Wire (press release) - Mon, 17 Nov 2014 04:56

Tekmira Announces Licensing and Collaboration Agreement With Dicerna
MarketWatch - Mon, 17 Nov 2014 04:56

Dicerna to License Tekmira LNP Technology in $24.5M Deal
Genetic Engineering & Biotechnology News - Mon, 17 Nov 2014 07:08



A Vaccine for Kidney Stones? Boston Pharmaceutical Company May Have It!
Allena Pharmaceuticals has discovered a potential treatment for hyperoxaluria, a metabolic condition which can culminate in calcium deposits in the kidneys. This occurs due to either an over-absorption or over-production of oxalates which, when ...
Air Herald - Thu, 20 Nov 2014 07:56

ACT Buys AGN, NBS Needs A Close Watch, No Pain For TRVN, TKMR Does A ...
Primary hyperoxaluria type 1 (PH1) is a rare, inherited liver disorder that often results in kidney failure, and for which there are no approved therapies. Under the agreement, Dicerna will pay Tekmira $2.5 million upfront and payments of $22 million ...
Nasdaq - Mon, 17 Nov 2014 21:17

Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena ...
On the same day, Tekmira Pharmaceuticals Corp. announced licensing of its proprietary lipid nanoparticle (LNP) delivery technology with Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) for exclusive use in Dicerna's primary hyperoxaluria type 1 (PH1) ...
SYS-CON Media (press release) - Tue, 18 Nov 2014 05:52

Morning Buzz: Globalstar (GSAT), Abengoa SA (ABGB), Celldex Therapeutics ...
TKMR has licensed its proprietary lipid nanoparticle delivery technology for exclusive use in DRNA's primary hyperoxaluria type 1 (PH1) development program. Under the agreement, Dicerna will pay Tekmira $2.5 million upfront and payments of $22 million ...
Wall Street Pit - Mon, 17 Nov 2014 06:21


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014